| 摘要 |
Provided herein is a hydrogen chloride salt of 1-(3-ter-butyl-1-p-tolyl-1H-pyrazol-5- yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-l H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-ter-butyl- 1-p-tolyl-lH-pyrazol-5-yl)-3-(5-fluoro-2-( l-(2-hydroxyethyl)-lH-indazol-5- yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of l-(3-ter-butyl-1-p-tolyl-lH- pyrazol-5-yl)-3-(5-fluoro-2-(l-(2-hydroxyethyl)-lH-indazol-5-yloxy)benzyl)urea hydrochloride Form B, processes for the preparation of said compositions, pharmaceutical compositions prepared by said methods, and the use of said compositions in the treatment of various diseases and disorders. |
